Editor's Note: Green and red arrows refer to intraday stock price movement.


AK Steel ( AKS) downgraded at Goldman from Buy to Neutral. Company is facing higher input costs.

The Buckle ( BKE) upgraded at Goldman from Sell to Neutral. $28 price target. Fashion cycle is easing for the company.

Corrections Corp of America ( CXW) downgraded at Barclays to Equal Weight from Overweight. Minimal margin improvement opportunities. Price target raised by a dollar to $28.

Ruddick ( RDK) downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $38 price target.

Research in Motion ( RIMM) downgraded at Kaufman from Buy to Hold. $60 price target. Company is facing increased competition.

Rovi ( ROVI) rated new Outperform at BMO. Coverage of ROVI was started with an Outperform rating. $60 price target. Growth should accelerate as its content and reach expands.

Reliance Steel ( RS) upgraded at Goldman from Neutral to Buy. Company has exposure to growth in the aerospace and energy markets.

Seattle Genetics ( SGEN) rated new Overweight at Piper Jaffray. $20 price target. Company is on the verge of bringing its first drug to market.

Symantec ( SYMC) upgraded at ISI from Hold to Buy. $22 price target. Company is executing better and is a potential takeover target.

Taleo ( TLEO) downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Maintain $30 price target.

Trinity Industries ( TRN) rated new Outperform at Wells Fargo. Rail supply industry appears to be at the beginning of a multi-year recovery.

Viropharma ( VPHM) rated new Overweight at Piper Jaffray. $20 price target. HAE drug should ultimately be able to generate $500 million of annual U.S. sales.
This article was written by a staff member of TheStreet.